Romania’s nuclear energy operator Nuclearelectrica reported a net profit of 102.7 million euros in the first quarter of 2025, marking an 8.8% decline compared to the same period last year. Despite the drop in profit, the company posted a strong operational performance, with revenues nearing 300 million euros—up 23.6% year-on-year—driven by increased electricity sales and higher market prices.
Electricity sales alone generated 288 million euros in revenue, supported by a 25.7% increase in the average selling price. However, rising expenses, particularly those related to contributions to the Energy Transition Fund, impacted earnings before interest, taxes, depreciation, and amortization (EBITDA), which dropped 8% to 141 million euros.
Cernavoda nuclear power plant produced approximately 2,721 GWh of electricity during the quarter, representing a slight decrease of 1.7% compared to Q1 2024. By the end of March, the company’s total assets rose slightly to 2.85 billion euros, up from 2.83 billion at the close of 2024. Liabilities, meanwhile, declined notably from 356 million euros to 286 million.
Looking ahead, Nuclearelectrica is working to diversify its business. In partnership with France’s Framatome, the company signed a long-term agreement in November to develop Lutetium-177 production at the Cernavoda plant. This medical isotope is used in cancer treatment. The infrastructure for isotope irradiation is expected to be completed by the end of 2027, with commercial operations beginning in 2028.
Cernavoda currently operates two nuclear reactors, each with a capacity of 700 MW, supplying around 20% of Romania’s electricity. The Romanian Government holds an 82.5% stake in Nuclearelectrica through the Ministry of Energy, while the remaining shares are traded on the Bucharest Stock Exchange.
